Venolex

Quick links to important sections

Venolex

Method of action: Angioprotective, Venotonic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Venolex

Property Description
Active ingredient Diosmin, Hesperidin (Micronized Purified Flavonoid Fraction)
Form Film-coated tablet (Oral formulation)
Pharmacological class Venoactive drug (Phlebotonic, Vascular Protector)
Common use Supporting venous tone and capillary resistance
Origin Derived (from natural citrus bioflavonoids)

Venolex is a pharmaceutical preparation classified as a venoactive drug or phlebotonic, a type of medicine utilized to support the structural integrity and functional dynamics of the veins and capillaries. It is designed for oral administration and supplied as a combination product. This classification signifies that the medicine is primarily intended to improve vascular tone and microcirculation. The use of this specific Diosmin and Hesperidin combination is clinically recognized for its systemic application in treating chronic venous weakness.

Composition and Form: Why are Diosmin and Hesperidin Micronized?

Venolex contains the active components Diosmin and Hesperidin, which are bioflavonoids of natural origin, often derived from citrus fruits. They are manufactured as a specialized Micronized Purified Flavonoid Fraction (MPFF). This combination is utilized as a therapeutic strategy.

The term micronized denotes a mechanical process that reduces the particle size of the components to increase their dissolution rate and subsequent absorption in the gastrointestinal tract. This process results in enhanced bioavailability compared to non-micronized forms. This distinction is paramount, as effective delivery of the active agents to the circulatory system is crucial for achieving their targeted effect on the vein walls.

How Does Venolex Generally Help Vascular Health?

Venolex generally supports vascular health by enhancing venous tone and increasing the overall resistance of the capillaries, which reduces abnormal leakage. This dual action facilitates better overall fluid dynamics in the tissue.

The combined bioflavonoid components act to mitigate inflammatory damage to the vessel lining by reducing the adherence of immune cells to the vascular wall. This structural support and anti-inflammatory activity reduce the excessive filtration of fluid into the surrounding tissues, which is the direct underlying cause of symptomatic swelling and discomfort related to chronic venous weakness.

What side effects are possible with Venolex?

Possible Side Effects and Safety Information

Venolex (referenced to Venetoclax) is associated with several distinct categories of adverse reactions and safety risks as documented in regulatory information. Patient monitoring and prophylactic measures are primary components of its safe use, especially during the initiation phase.

Adverse Reactions and Risks

Adverse Reaction Category Common Adverse Events (Very Common geq 10%)
Hematologic Neutropenia, Thrombocytopenia, Anemia
Gastrointestinal Diarrhea, Nausea, Vomiting
Infections Upper Respiratory Tract Infection, Pneumonia
General Fatigue, Musculoskeletal Pain, Edema

Clinically Significant and Serious Adverse Reactions

The most serious identified risk is Tumor Lysis Syndrome (TLS), which has occurred in patients treated with the drug. The risk is highest during the initial dose ramp-up phase. Prophylactic anti-hyperuricemics, adequate hydration, and close monitoring of blood chemistries are required to mitigate this risk. Fatal and serious Infections, including Pneumonia and Sepsis, have been reported; patients must be monitored for signs of infection such as fever.

Safety Restrictions and Monitoring

  • Drug Interactions: Concomitant use with strong CYP3A inhibitors is contraindicated during the initiation and ramp-up phase. Dose reductions are required when used with moderate CYP3A or P-gp inhibitors.
  • Immunization: The administration of live attenuated vaccines is restricted before, during, or after treatment until B-cell recovery.
  • Embryo-Fetal Toxicity: Based on its mechanism, the drug may cause embryo-fetal harm, and females of reproductive potential must use effective contraception during treatment and for a specified period after the last dose.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory documentation indicates that clinical experience with overdose involving the Diosmin/Hesperidin combination is limited. Overdose situations are primarily associated with the occurrence or worsening of expected adverse reactions, which is why immediate action is required upon suspicion of excessive intake.

Documented Overdose Manifestations

According to official prescribing information, the most frequently reported manifestations following excessive intake are related to the gastrointestinal and integumentary (skin) systems.

  • Gastrointestinal Events: Symptoms such as diarrhea, nausea, and abdominal pain have been documented in association with overdose.
  • Skin Events: Manifestations include pruritus (itching) and rash.

Official Emergency Action

The regulatory stance dictates immediate action when there is suspicion of having taken more than the recommended dosage, particularly if any adverse symptoms are present. You must seek immediate medical attention or consult your doctor or pharmacist immediately if an excess of the labeled dose has been consumed.

Management and Classification

The official product labels state that the management of an overdose should consist in treatment of clinical symptoms. This approach relies on symptomatic and supportive care. No specific antidote is documented in the regulatory guidelines for this medication. The officially recorded symptoms primarily relate to the known side effect profile, and the documentation does not explicitly classify severe or life-threatening outcomes directly tied to overdose.

Therapeutic Uses of Venolex

What Venolex treats: Main Uses and Benefits

The primary role of Venolex (Diosmin/Hesperidin MPFF) is to provide symptomatic support across domains related to venous and microcirculatory compromise, assisting in addressing symptoms related to physical discomfort and associated visible signs. The medication is relevant for both the symptomatic treatment of venous insufficiency and acute hemorrhoidal attacks.

This medicine is commonly used to help manage symptoms related to Chronic Venous Insufficiency (CVI), including feelings of heavy, tired, and aching legs, nocturnal leg cramps, and edema (swelling). It is also applied in conditions presenting with acute episodes of hemorrhoidal disease.

“The symptomatic relief provided by this medication contributes to improved comfort during periods of heightened symptoms.”

It may provide support that helps ease the overall symptom burden, assists with maintaining functional stability, and contributes to improved comfort during symptomatic periods. It is often used in settings where short-term symptomatic assistance is needed, such as alongside compression therapy for adjunctive symptomatic management.


Quick Fact: Use for Chronic Venous Discomfort Venolex may assist with managing symptoms that interfere with daily functioning, such as persistent leg heaviness and pain associated with long periods of standing or sitting.

Regulatory References

  1. Public Assessment Report for Repaven (Diosmin) Indications

Eligibility and Restrictions for Use

This section outlines the officially documented population eligibility rules for Venolex (Micronized Purified Flavonoid Fraction) as defined by authoritative government regulatory documents.

Eligibility Scope Regulatory Status
Populations for whom use is allowed Adults (Primary user population)
Populations for whom use is contraindicated Patients with known Hypersensitivity to the active substance or any excipients.
Age-Related Eligibility Restriction Status
Children and Adolescents (<18 years) Use Not Established (Safety and efficacy have not been determined).
Older Adults No specific restrictions or dosage adjustments are formally listed in the label based solely on advanced age.
Physiological/Conditional Restrictions Eligibility Status
Pregnancy Preferable to Avoid (Precautionary measure due to limited human data).
Breastfeeding Inadvisable/Not Recommended (Risk to the infant cannot be excluded due to unknown excretion in human milk).
Acute Hemorrhoidal Attack Conditional Use (Administration does not preclude treatment for other anal conditions; requires medical review if symptoms persist).

The official profile establishes an absolute prohibition based on hypersensitivity. Use is primarily established for adults, while specific restrictions are placed on pediatric, pregnant, and lactating populations due to insufficient or limited regulatory data.

What should I know about interactions with other medicines?

The official interaction profile for Venolex (Diosmin, Hesperidin Micronized Purified Flavonoid Fraction) is primarily defined by the regulatory review, which cites an absence of formally documented clinically significant interactions. This status is based on official government regulatory documents.

Official Interaction Profile Summary

Category Regulatory Status
Documented Interacting Medicines None listed in official regulatory information.
Mechanistic Basis of Interactions None documented; regulatory sources state no specific interaction studies were performed for the product.
Interaction-Related Restrictions No formal prohibitions or do-not-combine rules are listed based on interaction risk.

Interaction Classification and Constraints

Category Regulatory Status
Interaction Severity Classification No combinations are formally classified as contraindicated due to interaction risk.
Timing-Separation Rules None are mandated for co-administration with other medicines.

Connection to the Overall Interaction Profile

The regulatory documentation indicates that no clinically relevant drug interactions have been reported during post-marketing surveillance for Venolex. This documentation means the official labeling does not require specific dose adjustments or list specific substances to avoid, based on known interaction data. This profile is consistent with the product's official regulatory review and the lack of specific interaction data cited in government documents.

Mechanism of Action

Venolex, a combination of Diosmin and Hesperidin (MPFF), operates through a multi-target mechanism focused entirely on modulating the structure and function of the peripheral circulation, influencing three core physiological domains simultaneously.

Amplification of Peripheral Venous Tone

This mechanism targets the Venous Smooth Muscle Cells (VSMCs) to modulate the peripheral adrenergic pathway. The components potentiate and prolong the vasoconstricting signal of the body's natural norepinephrine (NE), directly resulting in a sustained increase in venous tone. This physiological effect reduces venous capacity and regulates the pooling of blood ( venous stasis) within the veins.

Modulation of Microvascular Integrity

The drug engages mechanisms that modulate the integrity of the vascular endothelium of the capillaries and venules. It achieves this by modulating the early stages of the microvascular inflammatory cascade, specifically by inhibiting the adherence and migration of leukocytes. This mechanistic action preserves the integrity of the capillary barrier, thereby normalizing capillary permeability and modulating the abnormal filtration of plasma fluid into the surrounding tissues.

Enhancement of Active Fluid Clearance

Venolex exerts a functional influence on the lymphatic system, which is responsible for tissue fluid drainage. By stimulating the smooth muscle contractility of the lymphatic vessels, the drug promotes enhanced lymphatic pumping action. This enhancement accelerates the active removal of interstitial fluid, contributing to fluid homeostasis in the tissue.

Dosage and Administration Information

How to Use Venolex: Official Administration Guidelines

Venolex is a medicine for topical use only, meaning it is applied directly to the skin. The instructions for its use are structured around the application process, frequency, and the amount to be applied.

Administration Protocol

Administration Scope Official Instruction
Route of Administration Topical (for use on the skin only)
Preparation Requirements The affected area must be cleaned and dried well before application.
Dosing Schedule Apply a thin film of the ointment.
Frequency Apply a minimum of twice daily or as often as necessary.
Post-Application Care The wound may be left unbandaged or an appropriate dressing can be applied, as advised by a healthcare professional.

Step-by-Step Procedure

The correct use of Venolex follows a defined sequence:

  1. Clean and dry the affected area of the skin thoroughly.
  2. Apply the ointment as a thin film over the prepared area.
  3. Repeat this application at least twice daily.
  4. Follow the guidance of a healthcare professional regarding covering the wound (e.g., leaving it unbandaged or applying a dressing).

This structured approach standardizes the medicine's application, specifying that the ointment should be applied to a prepared surface, defining the frequency, and determining the appropriate post-application wound management to be followed.

Recent Clinical Evidence

Research evidence / Overview of studies


Overview of Clinical Trials

The primary research focus for this compound has been in studies evaluating chronic pain conditions. The majority of studies were randomized, placebo-controlled trials (RCTs) involving adult participants with specific chronic pain diagnoses. Trials typically lasted between 12 and 24 weeks.

Research has explored whether the compound was associated with changes in various patient outcomes, including measures of pain intensity, physical function, and overall well-being.


Key Findings and Efficacy Data

  • Pain Measures: Multiple RCTs reported findings. Research explored whether the compound was associated with changes in moderate-to-severe pain. The primary measure in these studies was a numerical rating scale (NRS). In some trials, a difference favoring the compound over placebo was reported for symptom measures over a defined period, while other trials reported mixed results.
  • Quality of Life: Studies examined whether the compound could affect the quality of life, using standardized patient questionnaires that assessed daily activity and emotional state. Findings varied, with some participants reporting a difference in mood and sleep, but overall evidence remains limited.
  • Timeline of Reported Change: Research also examined the time to an initial reported change in pain.

Investigation of Action and Safety Profile

Studies were designed to investigate the compound's influence on specific neural pathways associated with pain transmission. This area of investigation has been explored in both preclinical and human studies.

  • Safety Assessments: Safety assessments in the clinical trials tracked adverse events, and records indicate mild nausea and fatigue were among those frequently reported. Researchers assessed for adverse events over an extended period. No major safety signals were identified based on the data collected within the limited duration and scope of the research conducted.
  • Long-term Data: Evidence regarding outcomes beyond the 24-week trial period is minimal. Long-term studies are currently underway to gather more comprehensive safety and outcome data.

Studies on Combination Therapy

Research has also investigated whether combination therapy was associated with a change in the severity of chronic pain.

  • Different outcomes were noted in trials comparing the compound plus a standard anti-inflammatory drug versus the standard drug alone. These studies were generally small and non-randomized. Additional research is needed to determine if one approach is associated with different outcomes compared to the other.

Important Note on Research

This summary is strictly descriptive of the clinical research and evidence base available. Consultation with a healthcare professional is important to determine if any treatment option is appropriate for individual health needs and circumstances.

Frequently Asked Questions (FAQ)

Common questions about Venolex (FAQ)

Q: Does Venolex have an instant effect, or does it take time to work?

Official data indicates that the time required to notice changes can vary. For chronic conditions, some studies observing symptoms like swelling (edema) found that the compound was associated with reported changes after approximately three months of continuous therapy.

Q: Can Venolex be taken at the same time as over-the-counter pain medication?

Regulatory information advises that the compound may affect the metabolism of certain medications, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. Regulatory documents state that this could potentially affect the absorption or effects of certain pain relievers.

Q: Does Venolex interact with prescription blood thinners?

The compound is described as having the potential to slow blood clotting. When co-administered with medications that also slow clotting, such as prescription anticoagulants/blood thinners, this may increase the risk of bruising and bleeding.

Q: Does Venolex affect mood, and can it cause anxiety or depression?

Official side effect profiles do not specifically list anxiety or depression as adverse events. However, nervous system side effects such as dizziness and headache have been reported, according to the Summary of Product Characteristics (SmPC) documents.

Q: Are specific laboratory tests or monitoring required while taking Venolex?

Specific monitoring may be advised by a healthcare provider, particularly for individuals with underlying health conditions such as liver issues. Additionally, those taking medications that affect blood clotting may need regular laboratory monitoring.

Q: Are there specific official warnings about operating heavy machinery while on Venolex?

No explicit prohibition on operating machinery is listed in regulatory documents. However, reported side effects include dizziness and fatigue. Individuals should consider how these reported side effects may affect their ability to operate machinery.

Q: What happens if a person misses a dose of Venolex?

Official product information advises that if a dose is forgotten, the person should take it as soon as they remember. They should then return to the standard dosing schedule to maintain their treatment.

Q: Are there specific foods or beverages that should be avoided while using Venolex?

Regulatory data advises patients to avoid consuming alcohol while taking the combination product. No specific foods are generally restricted in the official product information.

Q: How long does Venolex typically remain detectable in the body's system?

Pharmacokinetic data for the active components indicate the elimination half-life is documented as approximately 23 to 40 hours. This is the time it takes for half of the substance to be eliminated from the body.

Q: Are there any known interactions between Venolex and common herbal supplements or vitamins?

Official warnings state the compound may interact with certain herbal supplements that affect blood clotting (e.g., garlic or ginkgo). This interaction could potentially increase the overall risk of bleeding.

Q: Can people with pre-existing conditions like diabetes use Venolex?

People with underlying health conditions such as diabetes or bleeding disorders are generally advised to consult a healthcare professional before use. This consultation is important for determining individual appropriateness.

Q: Does Venolex cause drowsiness or impair a person's ability to drive?

Reported side effects include dizziness and headache, which could potentially interfere with driving or operating machinery. Individuals should consider how these reported effects may impact their ability to drive.

Q: Is there a risk of dependency or addiction associated with Venolex?

According to the official regulatory profile, Venolex is not classified as a controlled substance. The medicine is not described as habit-forming or associated with dependency risk in regulatory documents.

Q: What general steps should be taken if a side effect of Venolex is concerning?

Official guidance in the Patient Information Leaflet advises that if any severe or concerning side effects are experienced, the person should cease taking the product and seek guidance from a healthcare provider.

Q: Does Venolex interact with hormonal birth control pills?

The compound may affect certain liver enzymes and cellular pumps (P-glycoprotein) that metabolize and move medications. This could potentially alter the absorption and effects of some co-administered medicines, including hormonal contraceptives.

Q: Can Venolex influence or affect blood pressure readings?

Clinical studies have found that the compound did not significantly change systemic blood pressure readings in tested populations. However, a significant decrease in heart rate was observed in some reports.

Q: Is Venolex the same exact medicine as another drug with a similar name, like 'Veno-X'?

The combination product is available under several different brand names globally, such as Daflon, Ardium, and Osmigra. However, the core active components, Diosmin and Hesperidin (MPFF), remain the same.

Q: What is the expected duration of treatment with Venolex?

The duration of treatment is typically determined by the condition being managed. For chronic venous conditions, treatment is generally recommended for up to 3 to 6 months.

Q: Does Venolex need to be taken at a specific, consistent time of day?

Regulatory guidelines and common practice advise taking the oral form with a meal, such as after breakfast and dinner. This practice is often followed to help mitigate potential gastrointestinal side effects, according to regulatory guidelines.

Q: Does Venolex contain common allergens like gluten, lactose, or soy?

The official excipient lists for the film-coated tablet formulation include ingredients such as sodium lauryl sulphate and magnesium stearate. The official listing does not include common allergens such as lactose or gluten.

Q: Does Venolex interact with common cold or flu medications?

Official information indicates the compound may affect the metabolism of certain over-the-counter medications. This includes drugs like acetaminophen and some antihistamines, which could potentially alter their effects.

Q: What is the long-term risk to organs, such as the liver or kidneys, while taking Venolex?

While generally well-tolerated, some reports have noted liver-related problems as a possible adverse effect. Official guidance suggests that individuals with pre-existing liver issues may need to discuss the product with a healthcare provider for monitoring.

Q: Has Venolex been reviewed by regulatory bodies like the FDA or EMA?

Yes, the combination product has been subjected to review and verification by national regulatory bodies. Its official information is detailed in Summary of Product Characteristics (SmPC) and related regulatory documents.

Q: Can I use Venolex if I have a heart condition?

People with pre-existing cardiovascular conditions are generally advised to be cautious. Official guidance suggests that individuals with pre-existing cardiovascular conditions may require regular monitoring by a healthcare provider.

Q: Is Venolex effective for all severity levels or stages of the condition it is approved to treat?

Research reviewed by regulatory bodies suggests that the compound may be associated with symptom reduction across different stages of chronic venous disorders. It may also be used in conjunction with other therapies for more advanced stages.

Q: Is the development of a skin rash a frequently reported side effect of Venolex?

The official side effect profile lists skin disorders as a possible adverse event. This category includes reported instances of itching and rash.

Q: What are the safety concerns if Venolex is taken after its expiration date?

Regulatory advice states that patients should always read the label and that medications should not be taken past their expiration date. This is to ensure the effectiveness and stability of the product.

How should Venolex be stored and disposed of?

How to Store and Dispose of Venolex (Diosmin/Hesperidin)

Storage Conditions

Venolex tablets must be stored at controlled temperatures not exceeding 30 C to maintain their effectiveness and stability. The medication must be kept in the original carton or packaging and protected from excessive heat and moisture. To ensure safety, the product must be stored out of the sight and reach of children and pets, as mandated by regulatory guidelines.

Disposal Instructions

Official regulations prohibit the disposal of unused or expired Venolex tablets via wastewater or household waste. Disposal must be carried out according to local requirements for medicinal products to prevent environmental contamination. Patients should consult a pharmacist for guidance on proper drug take-back or disposal procedures in their area.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Venolex found in:

A-Z Index: